The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The importance of addressing cardiovascular risk in MPNs & unmet needs in this space
Marko Lucijanic, MD, PhD, School of Medicine University of Zagreb, Zagreb, Croatia, comments on the complexities of cardiovascular risk in myeloproliferative neoplasms (MPNs), emphasizing the importance of considering comorbidities beyond the MPN itself and the need for a more integrated approach. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
